04:25 PM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We reduce our target to $11 from $12, 9.5x our 2026 EPS, a sharp discount to AVTR's five-year historical forward P/E average of 21.7x, justified by the challenging environment the company is operating in. We maintain our 2025 EPS at $1.02 and lower our 2026 EPS forecast to $1.16 from $1.24. Following the sharp sell-off after the company's disappointing Q1 earnings release, combined with the news that long-term CEO Michael Stubblefield will be leaving his role, we expect shares to trade down at a slower pace going forward. Yet, we continue to think the company's performance will likely be challenged in the near term due to reduced demand in the education and government end markets and tariff headwinds. We see the increased focus on cost discipline in the current environment as positive. However, with the expanded cost transformation initiative target to $400M in gross run-rate savings by the end of 2027, returning to growth in the Laboratory Solutions segment will be the key near-term challenge, in our view.